A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Recruiting · NCT06707610 · Registry updated 2025-03-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors | Advanced Cancer; Advanced Solid Tumor | Recruiting | Phase 1 | 2025-03-12 | NCT06707610 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Allink Biotherapeutics Co., Ltd. | 4 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| D&H Cancer Research Center LLC | Margate | United States | 4 |
| Macquarie University | Sydney | Australia | 10 |
| NEXT Oncology | Fairfax | United States | 31 |
| Scientia Clinical Research Ltd | Randwick | Australia | 11 |